Abstract: The present invention provides pharmaceutical compositions comprising as an active ingredient a selective SGLT1 inhibitor (e.g., an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect), which have a wider range of inhibitory effect on carbohydrate absorption and a hypoglycemic effect caused by fructose ingestion at regular diets and therefore can exhibit a marked hypoglycemic effect, and which are suitable as agents for the prevention or treatment of diseases associated with hyperglycemia (e.g., diabetes, impaired glucose tolerance, diabetic complications, obesity).